In cells with Enhancer of zeste homolog 2 (EZH2) gain-of-function mutations, combinatorial inhibition of MEN1 using MI-503 or VTP50469 with EZH2 inhibitor Tazemetostat (EPZ-6438) has been shown to decrease tumor burden and survivability in a lymphoma xenograft model [163]. Here, EZH2 is linked to neoplasm.